Aging Metabolism Reduces Effectiveness of CAR-T Cell Therapy

Aging metabolism reduces effectiveness of CAR-T cell therapy

A Ludwig Cancer Research study has discovered that the metabolic decline that accompanies aging impairs the efficacy of CAR-T cell therapy, an immunotherapy in which T cells of the immune system are taken from patients, engineered to target cancer cells and reinfused into the same patients for treatment.

CAR-T cell therapy is revolutionizing cancer treatment. Here's how it works

Personalized medicine is already a reality in clinical practice, and CAR-T cell therapy is one of its most promising tools. This innovative approach, which involves genetically modifying the cells of the immune system, is transforming the way we treat not only cancer, but also other diseases.

CAR-T cell therapy is revolutionising cancer treatment – here’s how it works

Recreation of CAR-T cells attacking a cancerous melanoma cell. Nemes Laszlo/ShutterstockPersonalised medicine is already a reality in clinical practice, and CAR-T cell therapy is one of its most promising tools. This innovative approach, which involves genetically modifying the cells of the immune system, is transforming the way we treat not only cancer, but also other diseases. The CAR-T revolution is widely documented, with more than 1,000 cli…

Ground-floor research explores quality of life after new cancer treatment

Investigating the long-term effects of a new cancer treatment on patients is a lot like building a car while driving it. That’s the challenge faced by Hamilton Health Sciences (HHS) researcher and malignant hematologist Dr. Amaris Balitsky, who is studying the lasting impacts of CAR T-cell therapy, a specialized treatment that became available to Ontario patients with certain types of lymphoma just five years ago. In 2020, the HHS Juravinski Hos…

CAR-T therapy can be safely manufactured at hospital:Study

An ICMR-funded trial led by CMC Vellore demonstrated that CAR-T therapy, which uses a patient's own T cells to fight cancer, can be safely manufactured at the hospital and infused to treat patients in India at a low cost.

New Syndrome With CAR T-Cell Therapy in Autoimmune Diseases

Local immune effector cell–associated toxicity syndrome is a newly identified side effect observed in many patients receiving CD19-targeting CAR T-cell therapy for autoimmune conditions.